GeneDx Reports Third Quarter 2026 Financial Results
Reported third quarter 2026 revenue of $123.1 million, including $110.4 million in exome and genome revenue
Reported exome and genome volume growth of 25% year-over-year with accession growth of 28% year-over-year
GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the third quarter of 2026.
“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth,” said Katherine Stueland, CEO of GeneDx. “Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale. By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”
• Exome and genome test revenue grew to $110.4 million, an increase of 12% year- over-year.
• Exome and genome test result volume grew to 32,134, an increase of 25% year- over-year, with accession growth of 28% year-over-year.
• Adjusted gross margin of 72% in the third quarter of 2026 is up from 70% in the second quarter of 2026 and compares to 74% in the third quarter of 2025.
• Adjusted total operating expenses were $79.4 million, representing 65% of revenue.
• Adjusted net income was $8.6 million, up $8.2 million from the second quarter of 2026 and compared to adjusted net income of $16.1 million in the third quarter of 2025.
• Cash, cash equivalents, marketable securities and restricted cash was $171.1 million as of September 30, 2026.
(1) Adjusted gross margin, adjusted total operating expenses and adjusted net income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.
GeneDx has updated its 2026 guidance and has provided guidance for the fourth quarter of 2026. Management expects GeneDx to deliver:
Full Year 2026 Full Year 2026 Fourth Quarter Metric Previous Updated Guidance 2026 Guidance Guidance Revenue $475 to $490 $475 to $490 $135 million million million Exome and At least 30% At least 28% 34,500 tests genome volume growth growth Exome and At least 20% At least 17% $121 million genome revenue growth growth Adjusted gross Approximately Approximately At least 71% margin 70% 71% Adjusted net Positive Approximately Approximately $12 income $12 million million
• Announced genome testing portfolio enhancement with long-read whole genome sequencing, reflecting GeneDx's continued focus on genome innovation to expand diagnostic capabilities and deliver more answers to more patients.
• Launched additional customer experience features, including simplified test reports, easy ordering, and report guides to simplify genomic testing from ordering through understanding and communicating results.
• Launched a new online offering designed to expand accessibility of exome testing for pediatric patients with global developmental delay (GDD), intellectual disability (ID) or epilepsy by enabling families to initiate genetic testing online and connect with licensed healthcare providers who can review medical information, order testing, and deliver results without requiring traditional in-person visits.
• Collaborated with Mirum Pharmaceuticals to launch a sponsored testing program, providing no-cost exome testing for eligible patients with unexplained cholestasis, early onset cataracts, or suspected or confirmed peroxisome biogenesis disorder–Zellweger spectrum disorder (PBD-ZSD).
• Partnered with Beren Therapeutics P.B.C. to launch the NPC GenomeComplete Sponsored Testing Program, providing no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC).
• Expanded the number of state Medicaid programs covering whole genome sequencing to 25 with the addition of Arkansas and Utah Medicaid.
• Appointed Nicole Maassen, J.D. as Chief Patient Access Officer to lead Market Access and Government Affairs with a focus on advancing payer partnerships, building upon government relations efforts, and translating positive coverage policies into timely access for children who need testing.
• Published new data in collaboration with the clinical genetics team at Seattle Children’s demonstrating that implementing first-tier rapid genome sequencing (rGS) broadly across inpatient pediatric care units improves diagnostic rates, patient outcomes, and operational efficiency within health systems.
• Presented 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research highlighted:
◦ Scaling genomic interpretation with AI and machine learning: A GeneDx-led platform presentation explores machine learning to prioritize relevant copy number variants (CNVs), reflecting the company’s human-first, human-last approach to leveraging AI decision support tools in exome and genome sequencing analysis.
◦ Advancing exome and genome sequencing as standard of care: Research from more than 100,000 individuals with autism examines factors influencing molecular diagnostic yield, adding evidence to support broad genomic testing for complex neurodevelopmental conditions.
◦ Translating clinical data into actionable insights: Studies explore genotype- first reanalysis, emerging genotype-phenotype associations, rare variant detection and the health-economic value of first-line exome and genome sequencing.
◦ Accelerating gene discovery: Nine abstracts using GeneDx Infinity™, GeneMatcher and global research collaborations to identify novel disease- associated genes and expand understanding of developmental and neurodevelopmental disorders.
• Demonstrated progress toward making genomic newborn screening a scalable and accessible part of proactive healthcare at the International Consortium on Newborn Sequencing (ICoNS) conference, including new findings from the GUARDIAN study, which has enrolled 30,000 newborns with a 72.3% parental participation rate, demonstrating the feasibility and clinical value of genomic newborn screening across diverse populations.
• Partnered with the BRIDGES-NBS initiative to begin enrollment in Oregon as part of the nation's first coordinated, multi-state genomic newborn screening study. GeneDx serves as the integrated laboratory partner, providing genome sequencing and interpretation to screen up to 30,000 newborns for more than 700 actionable genetic conditions over two years.
GeneDx will host a conference call today, November 9, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.
GeneDx believes non-GAAP measures are useful in evaluating its operating performance. GeneDx uses this supplemental information to evaluate its ongoing operations and for internal planning and forecasting purposes. GeneDx believes that non-GAAP financial information, when taken collectively with its GAAP financial information, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Reconciliations of non-GAAP financial measures to the most directly comparable financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. We define non- GAAP financial measures as GAAP measures, excluding certain items such as stock- based compensation expense, depreciation and amortization, restructuring costs, changes in the fair value of financial liabilities, non-core lease costs, and other expenses that the Company believes are not indicative of its ongoing operations. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expectations for full year and fourth quarter 2026 revenue, exome and genome revenue and test volumes, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) future expansion of insurance coverage for exome and genome testing, and (v) the anticipated impacts of regulatory reimbursement changes . The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year
ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 23, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the SEC on August 3, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026, filed with the SEC on November 9, 2026, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward- looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
(1) Basic and diluted reported loss per share and Basic adjusted earnings per share are calculated based on 29,880,144 weighted average shares outstanding and Diluted adjusted earnings per share is calculated based on 30,756,054 weighted average shares outstanding for the three months ended September 30, 2026. Basic and diluted reported loss per share and Basic adjusted earnings per share are calculated based on 28,797,730 weighted average shares outstanding and Diluted adjusted earnings per share is calculated based on 30,152,510 weighted average shares outstanding for the three months ended September 30, 2025.
(2) Other represents interest expense, net, income tax expense, non-core lease costs, and costs related to legal reserves for all periods presented. For the three months ended September 30, 2026, Other also includes third party advisor fees related to our Revenue Cycle Transformation. For the three months ended September 30, 2025, Other also includes transaction costs incurred in connection with the acquisition of Fabric Genomics.
(1) Basic and diluted reported loss per share and Basic adjusted earnings per share are calculated based on 29,710,139 weighted average shares outstanding and Diluted adjusted earnings per share is calculated based on 30,144,132 weighted average shares outstanding for the three months ended June 30, 2026.
(2) For the three months ended June 30, 2026, Other represents interest expense, net, income tax benefit, non-core lease costs, and costs related to legal reserves.
September 30, 2026 (Unaudited) December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets: Current assets: Cash and cash equivalents $ 96,139 $ 104,997 Marketable securities 73,979 66,285 Accounts receivable 92,131 74,370 Inventory, net 21,703 13,951 Prepaid expenses and other current 12,943 8,685 assets Total current assets 296,895 268,288 Operating lease 32,404 23,412 right-of-use assets Property and equipment, net 53,531 45,693 Goodwill 1,641 13,520 Intangible assets, net 137,732 168,481 Other assets(1) 4,281 4,316 Total assets $ 526,484 $ 523,710 Liabilities and Stockholders’ Equity: Current liabilities: Accounts payable and $ 32,426 $ 57,645 accrued expenses Short-term lease 5,823 4,404 liabilities Other current liabilities 33,154 46,859 Total current liabilities 71,403 108,908 Long-term debt, net of 146,229 48,176 current portion Long-term lease liabilities 63,332 56,046 Other liabilities 71 1,641 Deferred taxes 760 757 Total liabilities 281,795 215,528 Stockholders’ Equity: Preferred stock — — Class A common stock 3 3 Additional paid-in capital 1,711,675 1,680,738 Accumulated deficit -1,466,878 -1,373,495 Accumulated other comprehensive (loss) -111 936 income Total stockholders’ equity 244,689 308,182 Total liabilities and stockholders’ $ 526,484 $ 523,710 equity
(1) Other assets includes $1.0 million of restricted cash as of both September 30, 2026 and December 31, 2025.
Nine months ended September 30, Operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net loss $ -93,383 $ -3,355 Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Depreciation and 20,418 18,343 amortization expense Stock-based 23,591 22,382 compensation expense Change in fair value of financial -2,760 2,320 liabilities Deferred tax expense 405 448 Legal reserves — 810 Change in third party -1,370 8,746 payor reserves Loss on extinguishment 6,565 — of debt Impairment loss 31,287 — Other 3,611 2,534 Change in operating assets and liabilities: Accounts receivable -17,982 -22,799 Inventory -7,823 -72 Accounts payable and -19,308 5,185 accrued expenses Other assets and -15,239 1,827 liabilities Net cash (used in) provided by operating -71,988 36,369 activities Investing activities Acquisition of business, net of cash — -33,195 acquired Purchases of -40,859 -36,535 marketable securities Proceeds from sales of marketable 3,172 — securities Proceeds from maturities of 29,175 33,955 marketable securities Purchases of property and equipment and -21,791 -14,670 development of internal-use software Net cash used in -30,303 -50,445 investing activities Financing activities Proceeds from long term debt, net of 146,027 — issuance costs Proceeds from offerings, net of — 25,568 issuance costs Proceeds from issuance of common stock 5,000 — from securities purchase agreement Proceeds from issuance of common stock 476 — from subscription agreements Proceeds from issuance of common stock 1,793 1,262 pursuant to employee stock purchase plan Exercise of stock 58 982 options Repayment of long-term debt, including -54,000 — prepayment penalty - Perceptive Repayment and principal payments for -4,447 -906 long-term debt - DECD Finance lease -1,473 -2,074 principal payments Net cash provided by financing 93,434 24,832 activities Net (decrease) increase in cash, cash -8,857 10,756 equivalents and restricted cash Cash, cash equivalents and restricted 105,989 86,202 cash, at beginning of period Cash, cash equivalents and restricted $ 97,132 $ 96,958 cash, at end of period(1) Supplemental disclosures of cash flow information Cash paid for interest $ 6,678 $ 4,835 Cash paid for taxes $ 2,394 $ 1,039 Purchases of property and equipment in $ 1,610 $ 4,472 accounts payable and accrued expenses Lease liability from obtaining $ 12,086 $ — right-of-use asset
(1) Cash, cash equivalents and restricted cash as of September 30, 2026 excludes marketable securities of $74.0 million.
Full text with the tables
Exhibit 99.1
GeneDx Reports Third Quarter 2026 Financial Results
•
Reported third quarter 2026 revenue of $123.1 million, including $110.4 million
in exome and genome revenue
•
Reported exome and genome volume growth of 25% year-over-year with accession
growth of 28% year-over-year
•
Expanded adjusted gross margin
(1)
to 72% and adjusted net income
(1)
to $8.6 million
•
Reiterating full year 2026 revenue guidance of $475 to $490 million
•
Hosting conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., November 9, 2026 —
GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and
improving health through the power of genomic data, today reported its financial
results for the third quarter of 2026.
“Our Q3 results reflect profitable execution in a growing market, as we
translate the rising demand for exome and genome testing into durable revenue
growth,” said Katherine Stueland, CEO of GeneDx. “Our priorities are clear:
improve the economics of our testing, expand utilization, and deliver leading
products at scale. By uniting these priorities with our clinical expertise and
differentiated exome and genome capabilities, we are bringing life-changing
answers to more families.”
Third Quarter 2026 Financial Results (Unaudited)
(1)
Revenue
• Revenue grew to $123.1 million, an increase of 5% year-over-year.
• Exome and genome test revenue grew to $110.4 million, an increase of 12% year-
over-year.
Exome and genome volume
• Exome and genome test result volume grew to 32,134, an increase of 25% year-
over-year, with accession growth of 28% year-over-year.
Gross margin
• Adjusted gross margin of 72% in the third quarter of 2026 is up from 70% in
the second quarter of 2026 and compares to 74% in the third quarter of 2025.
◦ GAAP gross margin was 70%.
Operating expenses
• Adjusted total operating expenses were $79.4 million, representing 65% of
revenue.
◦ Total GAAP operating expenses were $96.5 million.
Net income
• Adjusted net income was $8.6 million, up $8.2 million from the second quarter
of 2026 and compared to adjusted net income of $16.1 million in the third
quarter of 2025.
◦ GAAP net loss was $12.3 million.
Cash position
• Cash, cash equivalents, marketable securities and restricted cash was $171.1
million as of September 30, 2026.
(1) Adjusted gross margin, adjusted total operating expenses and adjusted net
income are non-GAAP financial measures. See appendix for a reconciliation of
GAAP to non-GAAP figures presented.
GeneDx 2026 Guidance
GeneDx has updated its 2026 guidance and has provided guidance for the fourth
quarter of 2026. Management expects GeneDx to deliver:
Full Year 2026 Full Year 2026 Fourth Quarter
Metric Previous Updated Guidance 2026 Guidance
Guidance
Revenue $475 to $490 $475 to $490 $135 million
million million
Exome and At least 30% At least 28% 34,500 tests
genome volume growth growth
Exome and At least 20% At least 17% $121 million
genome revenue growth growth
Adjusted gross Approximately Approximately At least 71%
margin 70% 71%
Adjusted net Positive Approximately Approximately $12
income $12 million million
Third Quarter 2026 and Recent Business Highlights
Strategic Expansion and Market Leadership
• Announced genome testing portfolio enhancement with long-read whole genome
sequencing, reflecting GeneDx's continued focus on genome innovation to expand
diagnostic capabilities and deliver more answers to more patients.
• Launched additional customer experience features, including simplified test
reports, easy ordering, and report guides to simplify genomic testing from
ordering through understanding and communicating results.
• Launched a new online offering designed to expand accessibility of exome
testing for pediatric patients with global developmental delay (GDD),
intellectual disability (ID) or epilepsy by enabling families to initiate
genetic testing online and connect with licensed healthcare providers who can
review medical information, order testing, and deliver results without requiring
traditional in-person visits.
• Collaborated with Mirum Pharmaceuticals to launch a sponsored testing program,
providing no-cost exome testing for eligible patients with unexplained
cholestasis, early onset cataracts, or suspected or confirmed peroxisome
biogenesis disorder–Zellweger spectrum disorder (PBD-ZSD).
• Partnered with Beren Therapeutics P.B.C. to launch the NPC GenomeComplete
Sponsored Testing Program, providing no-cost comprehensive genome sequencing for
eligible pediatric patients with clinical findings, family history, or biomarker
evidence suggestive of Niemann-Pick Disease Type C (NPC).
Expanded Coverage for Exome and Genome
• Expanded the number of state Medicaid programs covering whole genome
sequencing to 25 with the addition of Arkansas and Utah Medicaid.
• Appointed Nicole Maassen, J.D. as Chief Patient Access Officer to lead Market
Access and Government Affairs with a focus on advancing payer partnerships,
building upon government relations efforts, and translating positive coverage
policies into timely access for children who need testing.
Innovation and Clinical Leadership
• Published new data in collaboration with the clinical genetics team at Seattle
Children’s demonstrating that implementing first-tier rapid genome sequencing
(rGS) broadly across inpatient pediatric care units improves diagnostic rates,
patient outcomes, and operational efficiency within health systems.
• Presented 27 scientific abstracts at the American Society of Human Genetics
(ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are
advancing scientific discovery, earlier diagnosis and more precise care. GeneDx
research highlighted:
◦ Scaling genomic interpretation with AI and machine learning: A GeneDx-led
platform presentation explores machine learning to prioritize relevant copy
number variants (CNVs), reflecting the company’s human-first, human-last
approach to leveraging AI decision support tools in exome and genome sequencing
analysis.
◦ Advancing exome and genome sequencing as standard of care: Research from more
than 100,000 individuals with autism examines factors influencing molecular
diagnostic yield, adding evidence to support broad genomic testing for complex
neurodevelopmental conditions.
◦ Translating clinical data into actionable insights: Studies explore genotype-
first reanalysis, emerging genotype-phenotype associations, rare variant
detection and the health-economic value of first-line exome and genome
sequencing.
◦ Accelerating gene discovery: Nine abstracts using GeneDx Infinity™,
GeneMatcher and global research collaborations to identify novel disease-
associated genes and expand understanding of developmental and
neurodevelopmental disorders.
• Demonstrated progress toward making genomic newborn screening a scalable and
accessible part of proactive healthcare at the International Consortium on
Newborn Sequencing (ICoNS) conference, including new findings from the GUARDIAN
study, which has enrolled 30,000 newborns with a 72.3% parental participation
rate, demonstrating the feasibility and clinical value of genomic newborn
screening across diverse populations.
• Partnered with the BRIDGES-NBS initiative to begin enrollment in Oregon as
part of the nation's first coordinated, multi-state genomic newborn screening
study. GeneDx serves as the integrated laboratory partner, providing genome
sequencing and interpretation to screen up to 30,000 newborns for more than 700
actionable genetic conditions over two years.
Webcast and Conference Call Details
GeneDx will host a conference call today, November 9, 2026, at 4:30 p.m. Eastern
Time. Investors interested in listening to the conference call are required to
register online. A live and archived webcast of the event will be available on
the “Events” section of the GeneDx investor relations website at
https://ir.genedx.com/.
Non-GAAP Financial Measures
GeneDx believes non-GAAP measures are useful in evaluating its operating
performance. GeneDx uses this supplemental information to evaluate its ongoing
operations and for internal planning and forecasting purposes. GeneDx believes
that non-GAAP financial information, when taken collectively with its GAAP
financial information, may be helpful to investors because it provides
consistency and comparability with past financial performance. However, non-GAAP
financial information is presented for supplemental informational purposes only,
has limitations as an analytical tool, and should not be considered in isolation
or as a substitute for financial information presented in accordance with GAAP.
Reconciliations of non-GAAP financial measures to the most directly comparable
financial results as determined in accordance with GAAP are included at the end
of this press release following the accompanying financial data. We define non-
GAAP financial measures as GAAP measures, excluding certain items such as stock-
based compensation expense, depreciation and amortization, restructuring costs,
changes in the fair value of financial liabilities, non-core lease costs, and
other expenses that the Company believes are not indicative of its ongoing
operations. A reconciliation of non-GAAP guidance measures to corresponding GAAP
measures is not available on a forward-looking basis without unreasonable effort
due to the uncertainty of expenses that may be incurred in the future. Investors
are encouraged to review the related GAAP financial measures and the
reconciliation of these non-GAAP financial measures to their most directly
comparable GAAP financial measures and not rely on any single financial measure
to evaluate our business.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S.
Private Securities Litigation Reform Act of 1995, including statements regarding
our future performance and our market opportunity, including our expectations
for full year and fourth quarter 2026 revenue, exome and genome revenue and test
volumes, adjusted gross margin and adjusted net income. These forward-looking
statements generally are identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,”
“may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely
result,” and similar expressions. Forward-looking statements are predictions,
projections and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to differ
materially from the forward-looking statements in this press release, including
but not limited to: (i) our ability to implement business plans, goals and
forecasts, and identify and realize additional opportunities, (ii) the risk of
downturns and a changing regulatory landscape in the highly competitive
healthcare industry, (iii) the size and growth of the market in which we
operate, (iv) future expansion of insurance coverage for exome and genome
testing, and (v) the anticipated impacts of regulatory reimbursement changes .
The foregoing list of factors is not exhaustive. You should carefully consider
the foregoing factors and the other risks and uncertainties described in the
“Risk Factors” section of our Annual Report on Form 10-K for the fiscal year
ended December 31, 2025, filed with the U.S. Securities and Exchange Commission
(the “SEC”) on February 23, 2026, our Quarterly Report on Form 10-Q for the
fiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026, our
Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed
with the SEC on August 3, 2026, our Quarterly Report on Form 10-Q for the fiscal
quarter ended September 30, 2026, filed with the SEC on November 9, 2026, and
other documents filed by us from time to time with the SEC. These filings
identify and address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on forward-
looking statements, and we assume no obligation and do not intend to update or
revise these forward-looking statements, whether as a result of new information,
future events, or otherwise. We do not give any assurance that we will achieve
our expectations.
About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest
life through genomics. GeneDx combines unmatched clinical expertise, advanced
technology, and the power of GeneDx Infinity™ – the world’s largest rare disease
genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and
GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough
Device designation – enabling clinicians to deliver precise, fast, and
actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with
the most powerful AI-driven genomic intelligence. A genomics pioneer over the
last 25 years, diagnosing more than 4,800 genetic diseases and publishing more
than 1,100 research publications, GeneDx is building the network that will drive
the future of genomic precision medicine. For more information, visit genedx.com
and connect with us on LinkedIn, Facebook, and Instagram.
Investor Relations Contact:
[email protected]
Media Contact:
[email protected]
Volume & Revenue
…
…
…
…
…
…
…
…
… 3… 3… 27… 2… 25…
… 2… 3… 27… 3… 34…
… 3… 5… 2… 6… 1Q… 55… 4… 5… 3Q… 60…
──────────────────────────────────────────────────────────────────────────────
…
… $ 1… $ 1… $ 9… $ 10… $ 9…
…
…
… 9… 1… 1… 13… 1…
…
… 2… 2… 0… 2.6 1…
…
…
… 0… 0… 0… 1.1 1…
…
…
… $ 1… $ 1… $ 1… $ 12… $ 1…
Unaudited Select Financial Information
T…
m…
e…
S…
3…
2…
──────────────────────────────────────────────────────────────────────────────
C…
D… in
R… a… S… R… FV O… A…
a… c… c… of
f…
l…
…
… $ 1… $ — $ — $ — $ — $ — $ 1…
…
… 3… — — — — — 3…
…
… 1… — — — — — 1…
…
…
… 3… -… -… -… — — 3…
…
… 8… 1… 3… 18 — — 8…
…
… 6… % 7… %
…
…
… 1… -… -… 51 — — 1…
…
…
… 7… -… -… -… — -… 6…
…
…
…
… -… 6… 8… 8… — 3… 8…
…
…
…
… -… — — — — 1… —
…
…
… -… — — — — — -…
…
…
…
… -… — — — — 26 —
…
…
… $ -… $ 6… $ 8… $ 8… $ — $ 4… $ 8…
…
…
…
… $ -… $ 0…
…
…
…
…
… $ -… $ 0…
…
…
T…
m…
e…
S…
3…
2…
──────────────────────────────────────────────────────────────────────────────
C…
D… in
R… a… S… R… FV O… A…
a… c… c… of
f…
l…
…
… $ 1… $ — $ — $ — $ — $ — $ …
…
… 3… — — — — — …
…
… 1… — — — — — …
…
…
… 3… -… -… — — — …
…
… 8… 1… 2… — — — …
…
… 7… % … %
…
…
… 1… -… -… 1… — — …
…
…
… 6… -… -… -… — -… …
…
…
…
… -… 6… 1… 1… — 2… …
…
…
…
… -… — — — — 5… —
…
…
… -… — — — 3… -2 …
…
…
…
… -… — — — — 2… —
…
…
… $ -… $ 6… $ 1… $ 1… $ 3… $ 3… $ …
…
…
…
… $ -… $ …
…
…
…
…
… $ -… $ …
…
…
(1) Basic and diluted reported loss per share and Basic adjusted earnings per
share are calculated based on 29,880,144 weighted average shares outstanding and
Diluted adjusted earnings per share is calculated based on 30,756,054 weighted
average shares outstanding for the three months ended September 30, 2026. Basic
and diluted reported loss per share and Basic adjusted earnings per share are
calculated based on 28,797,730 weighted average shares outstanding and Diluted
adjusted earnings per share is calculated based on 30,152,510 weighted average
shares outstanding for the three months ended September 30, 2025.
(2) Other represents interest expense, net, income tax expense, non-core lease
costs, and costs related to legal reserves for all periods presented. For the
three months ended September 30, 2026, Other also includes third party advisor
fees related to our Revenue Cycle Transformation. For the three months ended
September 30, 2025, Other also includes transaction costs incurred in connection
with the acquisition of Fabric Genomics.
Unaudited Select Financial Information
T…
m…
e…
J…
3…
2…
──────────────────────────────────────────────────────────────────────────────
C…
D… in
R… a… S… R… FV O… A…
a… c… c… of
f…
l…
…
… $ 1… $ — $ — $ — $ — $ — $ …
…
… 2… — — — — — …
…
… 1… — — — — — …
…
…
… 3… -… -… -… — — …
…
… 7… 1… 5… 47 — — …
…
… 6… % … %
…
…
… 1… -… -… -… — — …
…
…
… 7… -… -… -… — -… …
…
…
… — — — — — — —
…
…
… -… 6… 6… 3… — 1… …
…
…
…
… -… — — — — 1… —
…
…
… 3… — — — -… — …
…
…
…
… 5… — — — — -… —
…
…
… $ -… $ 6… $ 6… $ 3… $ -… $ 2… $ …
…
…
…
… $ -… $ …
…
…
…
…
… $ -… $ …
…
…
(1) Basic and diluted reported loss per share and Basic adjusted earnings per
share are calculated based on 29,710,139 weighted average shares outstanding and
Diluted adjusted earnings per share is calculated based on 30,144,132 weighted
average shares outstanding for the three months ended June 30, 2026.
(2) For the three months ended June 30, 2026, Other represents interest expense,
net, income tax benefit, non-core lease costs, and costs related to legal
reserves.
GeneDx Holdings Corp.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
September 30, 2026
(Unaudited) December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets:
Current assets:
Cash and cash equivalents $ 96,139 $ 104,997
Marketable securities 73,979 66,285
Accounts receivable 92,131 74,370
Inventory, net 21,703 13,951
Prepaid expenses and other
current 12,943 8,685
assets
Total current assets 296,895 268,288
Operating lease 32,404 23,412
right-of-use assets
Property and equipment, net 53,531 45,693
Goodwill 1,641 13,520
Intangible assets, net 137,732 168,481
Other assets(1) 4,281 4,316
Total assets $ 526,484 $ 523,710
Liabilities and
Stockholders’ Equity:
Current liabilities:
Accounts payable and $ 32,426 $ 57,645
accrued expenses
Short-term lease 5,823 4,404
liabilities
Other current liabilities 33,154 46,859
Total current liabilities 71,403 108,908
Long-term debt, net of 146,229 48,176
current portion
Long-term lease liabilities 63,332 56,046
Other liabilities 71 1,641
Deferred taxes 760 757
Total liabilities 281,795 215,528
Stockholders’ Equity:
Preferred stock — —
Class A common stock 3 3
Additional paid-in capital 1,711,675 1,680,738
Accumulated deficit -1,466,878 -1,373,495
Accumulated other
comprehensive (loss) -111 936
income
Total stockholders’ equity 244,689 308,182
Total liabilities and
stockholders’ $ 526,484 $ 523,710
equity
(1) Other assets includes $1.0 million of restricted cash as of both September
30, 2026 and December 31, 2025.
GeneDx Holdings Corp.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share amounts)
Three Nine
mont… mon…
ended end…
Sept… Sep…
30, 30,
Rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Dia…
test $ 120… $ 113,… $ 333,… $ 299,…
rev…
Oth… 3,0… 3,220 6,551 7,168
rev…
Tot… 123… 116,… 339,… 306,…
rev…
Cost
of 37,… 32,2… 107,… 92,6…
ser…
Gro… 86,… 84,5… 232,… 213,…
pro…
Res…
and 17,… 19,8… 56,8… 47,4…
dev…
Sel…
gen… 79,… 67,9… 229,… 165,…
and
adm…
Imp… — — 31,2… —
loss
(Lo…
inc… -10… -3,2… -85,… 1,158
from
ope…
Non…
exp…
net
Cha…
in
fair
val… — -3,4… 2,760 -2,3…
of
fin…
lia…
Int…
exp… -1,… -562 -3,6… -2,0…
net
Loss
on
ext… — — -6,5… —
of
debt
Oth…
(ex… -94 -174 -138 274
inc…
net
Tot…
non… -1,… -4,1… -7,6… -4,0…
exp…
net
Loss
bef… -12… -7,3… -92,… -2,9…
inc…
tax…
Inc…
tax -26 -247 -405 -448
exp…
Net $ -12… $ -7,6… $ -93,… $ -3,3…
loss
Wei…
sha…
out…
of
Cla…
A 29,… 28,7… 29,… 28,…
com…
sto…
-
Bas…
and
Dil…
Loss
per
sha…
Cla…
A
com… $ -0.… $ -0.27 $ -3.15 $ -0.12
sto…
-
Bas…
and
Dil…
GeneDx Holdings Corp.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
Nine months ended
September 30,
Operating activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net loss $ -93,383 $ -3,355
Adjustments to
reconcile net loss to
net
cash (used in)
provided by operating
activities:
Depreciation and 20,418 18,343
amortization expense
Stock-based 23,591 22,382
compensation expense
Change in fair value
of financial -2,760 2,320
liabilities
Deferred tax expense 405 448
Legal reserves — 810
Change in third party -1,370 8,746
payor reserves
Loss on extinguishment 6,565 —
of debt
Impairment loss 31,287 —
Other 3,611 2,534
Change in operating
assets and
liabilities:
Accounts receivable -17,982 -22,799
Inventory -7,823 -72
Accounts payable and -19,308 5,185
accrued expenses
Other assets and -15,239 1,827
liabilities
Net cash (used in)
provided by operating -71,988 36,369
activities
Investing activities
Acquisition of
business, net of cash — -33,195
acquired
Purchases of -40,859 -36,535
marketable securities
Proceeds from sales of
marketable 3,172 —
securities
Proceeds from
maturities of 29,175 33,955
marketable
securities
Purchases of property
and equipment and -21,791 -14,670
development of
internal-use software
Net cash used in -30,303 -50,445
investing activities
Financing activities
Proceeds from long
term debt, net of 146,027 —
issuance costs
Proceeds from
offerings, net of — 25,568
issuance
costs
Proceeds from issuance
of common stock 5,000 —
from securities
purchase agreement
Proceeds from issuance
of common stock 476 —
from subscription
agreements
Proceeds from issuance
of common stock 1,793 1,262
pursuant to employee
stock purchase plan
Exercise of stock 58 982
options
Repayment of long-term
debt, including -54,000 —
prepayment penalty -
Perceptive
Repayment and
principal payments for -4,447 -906
long-term debt - DECD
Finance lease -1,473 -2,074
principal payments
Net cash provided by
financing 93,434 24,832
activities
Net (decrease)
increase in cash, cash -8,857 10,756
equivalents and
restricted cash
Cash, cash equivalents
and restricted 105,989 86,202
cash, at beginning of
period
Cash, cash equivalents
and restricted $ 97,132 $ 96,958
cash, at end of
period(1)
Supplemental
disclosures of cash
flow
information
Cash paid for interest $ 6,678 $ 4,835
Cash paid for taxes $ 2,394 $ 1,039
Purchases of property
and equipment in $ 1,610 $ 4,472
accounts payable and
accrued expenses
Lease liability from
obtaining $ 12,086 $ —
right-of-use asset
(1) Cash, cash equivalents and restricted cash as of September 30, 2026 excludes
marketable securities of $74.0 million.